BRÈVE

sur AMOEBA (EPA:ALMIB)

Amoéba progresses towards the commercialization of Axpera in 2026

Graphique de l'évolution du cours de l'action AMOEBA (EPA:ALMIB).

Amoéba, a greentech company based in Chassieu, has announced positive results for its Axpera product, used against mildew. Trials conducted in several French wine-growing regions have demonstrated significant effectiveness, with some winegrowers reducing their use of copper without loss of efficacy. Axpera offers an alternative in a context of tightening phytosanitary regulations in France.

Amoéba is continuing its regulatory process in the United States, Brazil, and Europe. Although some approvals have been delayed by budgetary constraints, progress is being made in California. In Brazil, additional studies are underway. In Europe, the process is well underway, with results expected in early 2026.

R. P.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de AMOEBA